Kamada Ltd. (KMDA) is a Healthcare stock trading at $7.33 (as of 2026-06-18), with a market capitalization of $435.53M and a trailing P/E of 20.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Kamada Ltd. develops and supplies plasma-derived protein therapeutics through proprietary products and distribution. It offers therapies such as rabies and cytomegalovirus prophylaxis, treatments for immune-related conditions, hepatitis B and varicella prophylaxis, and GLASSIA for AATD, and also distributes products including BRAMITOB and FOSTER.